<?xml version="1.0" encoding="UTF-8"?>
<p>In one study, Huang et al investigated the antiviral activity of GCV against HAdV types 3, 4, 8, 19, and 37 using polymerase chain reaction (PCR) and concluded that there was a significant, dose-dependent inhibitory effect on those serotypes responsible for EKC.
 <xref rid="CIT0046" ref-type="bibr">46</xref> Systemically, Bruno et al described the potential therapeutic effect of GCV in that the incidence of HAdV infections was significantly reduced in stem cell-transplant patients treated with GCV for human cytomegalovirus prophylaxis.
 <xref rid="CIT0045" ref-type="bibr">45</xref>
</p>
